YUMAB GmbH

YUMAB develops fully human antibodies for partners worldwide. The YUMAB®platform covers technologies from antibody discovery to antibody engineeringand lead optimization. Its in vitro and on-cell selection technologies providehigh success-rates to all types of antigens. YUMAB antibodies contain natural,close to germline sequences promising low immunogenicity and toxicity.Bioinformatic optimization and in vitro evolution technologies give directaccess to optimized leads.